Which company produces Cemiplimab?

Cemiplimab (Cemiplimab) is a new type of PD-1 inhibitor. Its original drug was jointly developed by the American biopharmaceutical company Regeneron Pharmaceuticals and Sanofi. As an immune checkpoint inhibitor, its research and development background and clinical application are landmark. By blocking the binding of PD-1 to its ligand, cimepilimab can restore the anti-tumor activity of T cells, thereby helping the body recognize and eliminate cancer cells. Compared with traditional chemotherapy or targeted drugs, the biggest advantage of immunotherapy drugs is that they can mobilize the body's own immune system to form a more lasting anti-cancer effect.

The drug was first approved in the United States, and its indications cover patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), as well as some patients with non-small cell lung cancer (NSCLC). Especially in the treatment of CSCC, cimepilimab is regarded as a breakthrough because the previous systemic treatments for this disease were relatively limited. With the development of overseas multi-center studies, the application of this drug has gradually expanded and has shown positive effects in multiple indications.

Currently, in the international market, cimepilimab has become an important member of the field of PD-1 inhibitors, competing with similar drugs such as nivolumab and pembrolizumab. Its clinical differentiation is mainly reflected in its unique indications for CSCC and BCC, which is also the key to establishing a differentiated advantage in immuno-oncology treatment.

In the Chinese market, cimepilimab has not yet been officially launched. If patients need to use the drug, they usually need to rely on cross-border medical treatment or overseas drug purchase channels. Whether we can enter the Chinese market and complete medical insurance negotiations in the future will directly affect patient accessibility.

Reference materials:https://www.libtayohcp.com/